CTCL
9
3
4
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
22.2%
2 terminated out of 9 trials
50.0%
-36.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
StrataCTX® as a Steroid Sparing Device
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
Ritlecitinib in CTCL
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)
A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL